Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Depression and Health Outcomes in Refractory Epilepsy
This study is currently recruiting patients.
Sponsored by: | National Institute of Neurological Disorders and Stroke (NINDS) |
---|---|
Information provided by: | National Institute of Neurological Disorders and Stroke (NINDS) |
Purpose
To define the benefits of antidepressant treatment or cognitive behavior therapy on mood, function, and quality of life in patients with depression and refractory epilepsy.
Condition | Treatment or Intervention | Phase |
---|---|---|
Depression Epilepsy |
Drug: sertraline Behavior: cognitive behavior therapy |
Phase III |
MedlinePlus related topics: Depression; Epilepsy
Study Type: Interventional
Study Design: Randomized
Expected Total Enrollment: 254
Study start: August 2001
This randomized clinical trial will be conducted to compare the drug sertraline to cognitive behavioral therapy on symptoms of depression, antiepileptic medication compliance, seizure frequency, and quality of life outcomes in patients with depression and a seizure disorder or epilepsy. Approximately 254 patients will be enrolled in this study over a period of five years. Individual participation will last approximately 16 weeks. Study participants will be chosen randomly to receive either the study medication (sertraline) or cognitive behavior therapy for 16 weeks. Sertraline is approved by the Food and Drug Administration (FDA). Subjects who receive cognitive behavior therapy will be provided with a one-hour individual session with a licensed clinical psychologist each week for 15 weeks. All study participants will attend scheduled clinic visits every 4 weeks for 16 weeks.
Eligibility
Ages Eligible for Study: 21 Years - 75 Years, Genders Eligible for Study: Both
Criteria
INCLUSION:
EXCLUSION:
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |